RxDoctor Payments Data

Mark Jones

Physician Assistant · San Antonio, TXNPI 1982949657

Payments from drug & device makers

$952in general payments, 2019–2025

Across 30 payments — averaging $31.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$347
  • Alkermes, Inc.$165
  • Johnson & Johnson$136
  • Lundbeck LLC$129
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$58
  • AbbVie$42
  • plus $76 from 3 others

What the payments were for

  • Food & beverage$84188%
  • Education$11112%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$952 in reported general payments places this provider in the 60th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$5,001
Medicare patients
21
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate40$125,317
VraylarCariprazine Hcl16$25,307
Aripiprazole74$3,860
Hydroxyzine Hcl78$2,146
Atomoxetine Hcl23$1,754
Fluvoxamine Maleate27$1,207
Trazodone Hcl126$1,041
Clozapine17$988
Ziprasidone Hcl40$958
Clomipramine Hcl15$864
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine19$851
Mirtazapine88$841
Amitriptyline Hcl44$824
Lurasidone Hcl20$746
Buspirone Hcl79$734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$136$125,31740 claims
AbbVieVraylar$42$25,30716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →